Previous 10 | Next 10 |
Penny stocks are shares of companies trading for less than $5, which makes them excellent targets for day traders. Their lower price also makes them ideal for some investors to want to leap at potentially grassroots opportunities. While the latter is few and far between, the former is somet...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Sam the Leigh / Shutterstock.com Mullen (NASDAQ: MULN ) stock is on the move Thursday following news of the EV company acquiring $150 million in funding for its purchase of ELMS assets. ELMS holds ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: CI Photos / Shutterstock.com CytomX Therapeutics (NASDAQ: CTMX ) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (NASDAQ: REGN ). This strategi...
Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer PR Newswire Collaboration will enable the development of investigational next-generation bispecific immunotherapies using Cyto...
- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX’s Probody ® and Regeneron's Veloci-Bi ® platforms - - CytomX to receive $30 million upfront payment with the potential fo...
CytomX Therapeutics, Inc. (CTMX) Q3 2022 Earnings Conference Call November 08, 2022, 05:00 PM ET Company Participants Chris Ogden - SVP of Finance and Accounting Sean McCarthy - CEO and Chairman Conference Call Participants Peter Lawson - Barclays Etz...
CytomX press release ( NASDAQ: CTMX ): Q3 GAAP EPS of -$0.35 misses by $0.05 . Revenue of $16.92M (-3.8% Y/Y) misses by $3.13M . For further details see: CytomX GAAP EPS of -$0.35 misses by $0.05, revenue of $16.92M misses by $3.13M
- Advancing wholly owned, next-generation conditionally activated therapeutics CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b), with INDs anticipated in 2023 - - CX-904, Company’s first clinical stage Probody T-cell bispecific (EFGRxCD3), con...
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that preclinical data for CX-801, its conditionally activated cytokine program, will be presented ...
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022, after ...
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
CytomX Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...